Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for HALO
11.37
+0.14 (1.25%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.08 - 11.56
52 week 6.96 - 17.78
Open 11.21
Vol / Avg. 0.00/1.93M
Mkt cap 1.49B
P/E     -
Div/yield     -
EPS -0.56
Shares 129.49M
Beta 2.29
Inst. own 83%
Feb 27, 2017
Q4 2016 Halozyme Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 7, 2016
Q3 2016 Halozyme Therapeutics Inc Earnings Call
Nov 7, 2016
Q3 2016 Halozyme Therapeutics Inc Earnings Release
Sep 15, 2016
Halozyme Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference
Sep 8, 2016
Halozyme Therapeutics Inc at Robert W Baird Global Healthcare Conference - Webcast
Sep 7, 2016
Halozyme Therapeutics Inc at Wells Fargo Securities Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -90.87% -23.86%
Operating margin -71.40% -20.33%
EBITD margin - -19.08%
Return on average assets -40.13% -18.54%
Return on average equity - -76.42%
Employees 216 -
CDP Score - -

Address

11388 Sorrento Valley Rd
SAN DIEGO, CA 92121-1345
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Officers and directors

Connie L. Matsui Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Helen I. Torley President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Laurie D. Stelzer Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Mark J. Gergen J.D. Chief Operating Officer, Senior Vice President
Age: 53
Bio & Compensation  - Reuters
Harry J. Leonhardt Esq. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 59
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 44
Bio & Compensation  - Reuters
James M. Daly Director
Age: 54
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey William Henderson Independent Director
Age: 51
Bio & Compensation  - Reuters